Obagi Medical partners with VIO Med Spa for the ALOHA Program to assess Obagi® saypha® MagIQ™ across multiple locations.
Quiver AI Summary
Obagi Medical has partnered with VIO Med Spa to launch the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program, which focuses on evaluating the performance of Obagi® saypha® MagIQ™ fillers through a structured, multi-site assessment. VIO Med Spa was chosen for its rapid growth and dedication to high-quality aesthetic treatments. The collaboration aims to collect real-world evidence on the filler’s effectiveness in diverse settings, enhancing patient outcomes and providing comprehensive protocols to improve satisfaction. This partnership underscores Obagi's commitment to evidence-based aesthetics solutions and is set to begin with immersive training at VIO University.
Potential Positives
- Obagi Medical has partnered with VIO Med Spa, a rapidly growing leader in advanced aesthetic treatments, enhancing its market presence and credibility in the aesthetic medicine field.
- The ALOHA Program will generate real-world evidence on the performance of Obagi® saypha® MagIQ™, which could strengthen the brand's products through validated clinical results.
- Obagi Medical is recognized as the fastest-growing professional skincare brand in the U.S. in 2024, highlighting its significant market momentum and consumer interest.
- The collaboration emphasizes comprehensive protocols aimed at boosting patient satisfaction and achieving high-quality outcomes, which could lead to increased brand loyalty and repeat business.
Potential Negatives
- The press release does not provide any specific data or metrics to support the claims about the efficacy or success of the ALOHA Program, which could lead to skepticism about the partnership's potential outcomes.
- There is no mention of how potential risks or adverse effects of the Obagi® saypha® MagIQ™ filler will be monitored or communicated, which is critical in a medical aesthetic context.
- The press release focuses primarily on VIO Med Spa's attributes and expertise rather than detailing how Obagi Medical will directly benefit from this partnership, which may raise concerns about the perceived equal value in the collaboration.
FAQ
What is the ALOHA Program by Obagi Medical?
The ALOHA Program focuses on real-world evaluation of Obagi® saypha® MagIQ™ filler in aesthetic practices to gather data on performance and patient experience.
Who is VIO Med Spa?
VIO Med Spa is an award-winning franchise offering advanced aesthetic and wellness treatments at numerous locations nationwide.
What technology does Obagi® saypha® MagIQ™ use?
This filler utilizes MACRO Core Technology to provide a stable hyaluronic acid matrix for natural-looking results and consistent performance.
How will data be collected in the ALOHA Program?
Standardized data will be collected across multiple VIO Med Spa locations to assess clinical performance and enhance patient care.
Who leads the partnership for ALOHA Program?
The partnership is led by industry experts including Drew Fine, U.S. General Manager of Obagi, and Dr. Alan Durkin, Chief Medical Officer of VIO Med Spa.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$WALD Hedge Fund Activity
We have seen 33 institutional investors add shares of $WALD stock to their portfolio, and 25 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ZENO EQUITY PARTNERS LLP removed 3,082,963 shares (-20.1%) from their portfolio in Q3 2025, for an estimated $6,104,266
- NAMAN CAPITAL LTDA removed 776,722 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,537,909
- TRUXT INVESTMENTOS LTDA. removed 757,700 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,500,246
- UBS GROUP AG removed 745,165 shares (-88.9%) from their portfolio in Q4 2025, for an estimated $1,400,910
- MILESTONES ADMINISTRADORA DE RECURSOS LTDA. added 225,677 shares (+10.3%) to their portfolio in Q3 2025, for an estimated $446,840
- AMITELL CAPITAL PTE LTD removed 210,069 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $415,936
- BLACKROCK, INC. added 104,203 shares (+5.5%) to their portfolio in Q3 2025, for an estimated $206,321
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$WALD Analyst Ratings
Wall Street analysts have issued reports on $WALD in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 01/14/2026
- Canaccord Genuity issued a "Buy" rating on 11/25/2025
To track analyst ratings and price targets for $WALD, check out Quiver Quantitative's $WALD forecast page.
$WALD Price Targets
Multiple analysts have issued price targets for $WALD recently. We have seen 3 analysts offer price targets for $WALD in the last 6 months, with a median target of $3.0.
Here are some recent targets:
- Sydney Wagner from Jefferies set a target price of $2.0 on 01/14/2026
- Susan Anderson from Canaccord Genuity set a target price of $4.0 on 11/25/2025
- Dana Telsey from Telsey Advisory Group set a target price of $3.0 on 11/25/2025
Full Release
NEW YORK and STRONGSVILLE, Ohio, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced VIO Med Spa as a launch partner for the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. VIO Med Spa was selected for its rapid growth, expert-led approach to advanced aesthetic treatments, and dedication to delivering high-quality, results-driven care across its expanding national network of locations.
Through this real-world evaluation collaboration, VIO Med Spa will conduct a structured, multi-site assessment of Obagi® saypha® MagIQ™ across its practices. The program will leverage VIO Med Spa’s strengths in innovative injectables, personalized wellness protocols, and patient-focused education to generate robust real-world evidence on the filler’s performance in diverse, high-volume aesthetic environments.
“At VIO Med Spa, we’re committed to elevating aesthetic medicine through clinical excellence, innovation, and exceptional patient outcomes,” said Dr. Alan Durkin, Chief Medical Officer of VIO Med Spa. “Obagi’s ALOHA Program perfectly aligns with our mission by emphasizing real-world data and integrated skincare-injectable protocols. This partnership allows us to contribute meaningful insights that enhance results for our patients and advance the industry as a whole.”
The ALOHA Program evaluates both clinical performance and patient experience while providing providers with comprehensive Obagi protocols to boost satisfaction, build lasting relationships, and achieve consistent, high-quality outcomes. Standardized data will be collected across participating VIO Med Spa locations. The program kicks off at the upcoming VIO University program which includes 2 days of immersive expert led training for the VIO network of practices.
“Partnering with a dynamic, growth-oriented leader like VIO Med Spa reinforces Obagi’s commitment to launching aesthetics solutions grounded in authentic, practice-based evidence,” said Drew Fine, U.S. General Manager, Professional Channel. “The ALOHA collaboration with VIO Med Spa brings together clinical expertise, operational scale, and a shared passion for transformative patient care across the evolving med spa landscape.”
Obagi® saypha® MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable three-dimensional hyaluronic acid matrix. The technology is designed to deliver natural-looking results with category-leading performance, including high usable HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile¹.
For more information about ALOHA, visit https://obagi-professional.com .
About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,² Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website,
https://www.obagi.com
.
About VIO Med Spa
VIO Med Spa is a nationally recognized, award-winning franchise of full-service medical spas specializing in advanced aesthetic and wellness treatments, including injectables, skin rejuvenation, body contouring, facials, and more. With dozens of locations nationwide and a focus on clinical excellence and patient safety, VIO Med Spa delivers innovative, results-oriented care led by expert providers. For more information, visit
www.viomedspa.com
.
About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. For more information please visit:
https://ir.waldencast.com
.
Media Contact:
[email protected]
Source: Waldencast plc
¹ Puljic A, Frank K, Cohen J, Otto K, Mayr J, Hugh-Bloch A, Kuroki-Hasenöhrl, D. A Scientific Framework for Comparing Hyaluronic Acid Filler Crosslinking Technologies. Gels. 2025; 11(7):487
² Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)
